Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

116

Participants

Timeline

Start Date

September 26, 2017

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

High Risk Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

DRUG

Cytarabine

Given IV

BIOLOGICAL

Filgrastim

Given SC

DRUG

Fludarabine

Given IV

DRUG

Idarubicin

Given IV

BIOLOGICAL

Pegfilgrastim

Given SC

DRUG

Venetoclax

Given PO

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER